Health and Healthcare
3SBio IPO: Chinese Biotech Success
Published:
Last Updated:
3SBio Inc. (SSRX-NASDAQ) opened at a premium to its pricing out of the chute today. The company priced 7.7 million ADR shares at $16.00, and the first print was $17.50. The original range was $12.00 to $14.00 set last month, so this one may be greeted with some less optimism from IPO traders looking for undervalued and unknown stocks.
SSRX is a Chinese biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China; main focal areas are anemia and platelet count. Underwriters were UBS as the sole book-runner and CIBC World markets and Pacific Growth Equities listed as co-managers. This $275 million implied market cap at the original terms is now closer to $370 million after the premium open. Jon C. Ogg, February 7, 2007
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Editors' Picks
